HENDERSON, Nev., Aug. 16,
2022 /PRNewswire/ -- VolitionRx Limited
(NYSE: VNRX) ("Volition"), a multi-national
epigenetics company, has announced the appointment of
Mickie Henshall to its board
of directors effective August 15,
2022. Ms. Henshall was also appointed as a
member of the Compensation Committee and the Nominations and
Governance Committee.
Mickie is a seasoned marketing executive with over 20 years of
experience in developing and implementing marketing and sales
strategies within the IVD, clinical, and life science industries.
Early on in her career, Ms. Henshall served as Associate Director
of Diagnostics Marketing at Illumina, Inc. and has subsequently led
global marketing operations at Biotix, Inc., Accriva Diagnostics,
Inc. (acquired by Werfen Life), Agena Bioscience, Inc., and WGA
(Genomic Life, Inc.). Mickie is currently Chief Marketing Officer
at REALM IDx, Inc., a pioneering integrated diagnostics
company.
Dr. Martin Faulkes, Executive
Chairman of Volition, said, "We're delighted to have attracted
someone of Mickie's caliber to Volition's board. Mickie's global
marketing skill set and expertise, within the life sciences sector,
will be vital to us as we progress towards full commercialization
and bring our transformational Nucleosomics™ technology to
market."
Commenting on her appointment, Mickie
Henshall said, "I'm joining Volition at a significant stage
in the company's development with the Nu.Q® Vet test recently
licensed to Heska, an industry leader, and Nu.Q® NETs achieving CE
marking. I believe that there is enormous potential for Volition to
revolutionize the diagnosis of life-altering diseases through its
Nu.Q® product portfolio. I look forward to supporting the board and
senior leadership team in realizing Volition's mission."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's Nu.Q® technology go to:
www.volition.com
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients but also improve their quality of
life. The tests are based on the science of Nucleosomics™, which is
the practice of identifying and measuring nucleosomes in the
bloodstream or other bodily fluid - an indication that disease is
present. Volition is primarily focused on human diagnostics and
monitoring but also has a subsidiary focused on animal diagnostics
and monitoring.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. The address for Volition's
website is included in this document as an inactive textual
reference only.
Volition Enquiries:
Louise Batchelor/Debra Daglish, Volition
mediarelations@volition.com
+44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
potential uses, benefits and effectiveness of its Nucleosomics™
technology platform, including the Nu.Q® NETs test. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests, a failure by the marketplace to accept
Volition's Nu.Q® NETs test or other products based on its
Nucleosomics™ platform; Volition's failure to secure adequate
intellectual property protection; Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; Volition will face fierce competition and
its intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring
markets and their rapid technological change; downturns in domestic
and foreign economies; and other risks, including those identified
in Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Forward-looking statements are based on current
expectations, estimates and projections about Volition's business
based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade
names referred to in this press release are the property of their
respective owners.
Photo -
https://mma.prnewswire.com/media/1879024/VolitionRx_Limited.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-appoints-mickie-henshall-as-an-independent-director-301606551.html
SOURCE VolitionRx Limited